Literature DB >> 1524083

Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku.

R A Isern1, M Yaneva, E Weiner, A Parke, N Rothfield, D Dantzker, S Rich, F C Arnett.   

Abstract

PURPOSE: Patients with primary pulmonary hypertension (PPH) frequently have Raynaud's phenomenon, serum antinuclear antibodies (ANAs), and/or pulmonary vascular lesions similar to those seen in certain connective tissue diseases, especially scleroderma. A number of relatively disease-specific autoantibodies have been described in connective tissue diseases but have not been studied in patients with PPH. Therefore, sera from PPH patients were studied for a variety of autoantibodies, seeking a possible link between this pulmonary disorder and connective tissue diseases. PATIENTS AND METHODS: Sera from 31 patients with PPH and 24 with secondary pulmonary hypertension (SPH) were studied for the following autoantibodies: anti-centromere (indirect immunofluorescence of Hep-2 cells), anti-CENP-B by immunoblotting and enzyme immunoassay (EIA) using cloned CENP-B fusion protein, anti-topoisomerase I (Scl-70), anti-Ku using immunoblotting of affinity purified antigens, anti-cardiolipin using EIA, and anti-Ro (SS-A), La (SS-B), Sm, nRNP, Jo-1, PM-Scl, and Mi-2 by counter-current immunoelectrophoresis.
RESULTS: Anti-Ku antibodies were found in 23% of patients with PPH, 4% with SPH, and none of 24 normal controls (PPH versus SPH, p = 0.06: PPH versus controls, p = 0.01). Antibodies to CENP-B were found in one patient each with PPH and SPH, anti-topoisomerase I in one with SPH, and anti-Ro (SS-A) and La (SS-B) in one with PPH. Overall, 12 patients (39%) with PPH had Raynaud's phenomenon or positive ANA results, with 9 (29%) having more specific autoantibodies associated with connective tissue diseases.
CONCLUSIONS: These results further suggest a link between at least a subgroup of patients with PPH and autoimmune connective tissue diseases, with anti-Ku antibodies being a possible new serologic marker.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1524083     DOI: 10.1016/0002-9343(92)90238-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  19 in total

1.  Altered immune phenotype in peripheral blood cells of patients with scleroderma-associated pulmonary hypertension.

Authors:  Michael G Risbano; Christina A Meadows; Christopher D Coldren; Tiffany J Jenkins; Michael G Edwards; David Collier; Wendy Huber; Douglas G Mack; Andrew P Fontenot; Mark W Geraci; Todd M Bull
Journal:  Clin Transl Sci       Date:  2010-10       Impact factor: 4.689

Review 2.  Pulmonary hypertension, antiphospholipid antibodies, and syndromes.

Authors:  Ronald A Asherson; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

Review 3.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Scleromyositis: a scleroderma/polymyositis overlap syndrome.

Authors:  S Jablonska; M Blaszczyk
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

5.  The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension.

Authors:  Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

Review 6.  Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension.

Authors:  Patrick Crosswhite; Zhongjie Sun
Journal:  J Hypertens       Date:  2010-02       Impact factor: 4.844

Review 7.  Genomics of pulmonary arterial hypertension: implications for therapy.

Authors:  Mark W Geraci; Todd M Bull; Rubin M Tuder
Journal:  Heart Fail Clin       Date:  2010-01       Impact factor: 3.179

Review 8.  Pulmonary arterial hypertension in connective tissue diseases.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Heart Fail Clin       Date:  2012-07       Impact factor: 3.179

Review 9.  Immune and inflammatory mechanisms in pulmonary arterial hypertension.

Authors:  Hala El Chami; Paul M Hassoun
Journal:  Prog Cardiovasc Dis       Date:  2012 Sep-Oct       Impact factor: 8.194

10.  Clinical risk factors for portopulmonary hypertension.

Authors:  Steven M Kawut; Michael J Krowka; James F Trotter; Kari E Roberts; Raymond L Benza; David B Badesch; Darren B Taichman; Evelyn M Horn; Steven Zacks; Neil Kaplowitz; Robert S Brown; Michael B Fallon
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.